Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCI-110 · 1 trial · 1 indication
Absolute change from baseline in revised version of YGTSS-R-TTS as a continuous endpoint at week 12 of the respective treatment period. The Global Severity Score has a range of 0- 100. A higher score on the scale suggests a more severe Tic, or a greater impact the Tic has on the person's life.
| Arm | Type | Description |
|---|---|---|
| SCI-110 | EXPERIMENTAL | Cannabinoid-based medication consisting of Dronabinol and PEA |
| Dronabinol | PLACEBO_COMPARATOR | Placebo matched in taste, odour and appearance to SCI-110 |
| Name | Type | Description |
|---|---|---|
| SCI-110 | DRUG | SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day. |
| Placebo | OTHER | Pill that matches in taste, odour and appearance to SCI-110 active pills |
Inclusion Criteria: 1. Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) 2. Male and female subjects with an age between ≥18 and ≤65 years 3. Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) \>14 4. Clinical Glo...
SCI-110 is an investigational small molecule being developed for the treatment of Tourette Syndrome in adults. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in a randomized, double-blind, placebo-controlled trial to evaluate its safety and efficacy.
SCI-110 is being developed by SciSparc Ltd., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol SPRC. SciSparc is conducting clinical trials to evaluate the drug's potential as a treatment for Tourette Syndrome.
SCI-110 is currently in Phase 2 clinical development. The drug is being evaluated in a Phase 2 trial for the treatment of Tourette Syndrome. As an investigational drug, it has not yet received approval from regulatory agencies and remains in active clinical development.
SCI-110 is being studied in a Phase 2 clinical trial with the identifier NCT05126888, titled "SCI-110 in the Treatment of Tourette Syndrome." This randomized, double-blind, placebo-controlled trial is planned to enroll 164 participants aged 18 years and older across the United States, Germany, and Israel.
No, SCI-110 is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for the treatment of Tourette Syndrome. The drug has not yet completed the clinical development process required for regulatory approval and remains under investigation.